acceptance for participation. A secondary objective of the application process is to track enrollment in courses and training programs over time.

OMB approval is requested for 3 years. There are capital, operating, and/or maintenance costs of $98,022. The total estimated annualized burden hours are 2,210.

ESTIMATED ANNUALIZED BURDEN HOURS

Type of applicants	Estimated number of applicants	Estimated number of applications per applicant	Maximum burden hours per application	Estimated total annual burden hours requested
Doctoral Level	6,488	1	20/60	2,163
Students	82	1	20/60	27
Other	59	1	20/60	20

Dated: September 25, 2013.

Laura Lee,

Project Clearance Liaison, Clinical Center, National Institutes of Health.

[FR Doc. 2013–24074 Filed 10–1–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Submission for OMB Review; 30-day Comment Request; Quantification of Behavioral and Physiological Effects of Drugs Using a Mobile Scalable Device

SUMMARY: Under the provisions of Section 3507(a)(1)(D) of the Paperwork Reduction Act of 1995, the National Institute on Drug Abuse (NIDA), the National Institutes of Health (NIH) has submitted to the Office of Management and Budget (OMB) a request for review and approval of the information collection listed below. This proposed information collection was previously published in the **Federal Register** on March 29, 2013, Vol.78, No.61, pages 19273–19274, and allowed 60-days for public comment. No public comments were received. The purpose of this notice is to allow an additional 30 days for public comment. The National Institute on Drug Abuse (NIDA), the National Institutes of Health, may not conduct or sponsor, and the respondent is not required to respond to, an information collection that has been extended, revised, or implemented on or after October 1, 1995, unless it displays a currently valid OMB control number.

Direct Comments to OMB: Written comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the: Office of Management and Budget, Office of Regulatory Affairs, *OIRA_submission@omb.eop.gov* or by fax to 202–395–6974, Attention: NIH Desk Officer.

DATES: *Comments Due Date:* Comments regarding this information collection are best assured of having their full effect if received within 30-days of the date of this publication.

FOR FURTHER INFORMATION CONTACT: To obtain a copy of the data collection plans and instruments, submit comments in writing, or request more information on the proposed project contact: Dr. Steve Gust, National Institute on Drug Abuse, 6001 Executive Blvd., Bethesda, MD 20892, or call non-toll-free number (301) 443–6480 or Email your request, including your address to: *sgust@nida.nih.gov.* Formal requests for additional plans and instruments must be requested in writing.

Proposed Collection: Quantification of Behavioral and Physiological Effects of Drugs Using a Mobile Scalable Device, 0925-New, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH).

Need and Use of Information Collection: This study will examine the effectiveness of a mobile scalable device to detect the impairing effects of different drugs. The primary purpose of the data collected is to determine eligibility in a driving simulation study and to verify the effectiveness of the experimental manipulations. The findings will provide valuable information concerning the utility and effectiveness of mobile, smartphone/tablet-based neurocognitive assessment that can provide a multifactorial evaluation of cognitive functioning associated with impaired driving.

OMB approval is requested for 18 months. There are no costs to respondents other than their time. The total estimated annualized burden hours are 859.

ESTIMATED ANNUALIZED BURDEN HOURS

Form name	Type of respondent	Number of respondents	Number of responses per respondent	Average burden per response (in hours)	Per annual hour burden
Phone Screening	Adults	100	1	10/60	17
Consent Process, In-Person Screening Adderall	Adults	.....	.....	45/60	75
Consent Process, In-Person Screening Xanax	Adults	100	.....	45/60	75
Consent Process, In-Person Screening Cannabis	Adults	.....	.....	45/60	75
Driving Survey	Adults	.....	1	15/60	18
Realism Survey	Adults	.....	1	3/60	4
Sleep and Intake Questionnaire	Adults	.....	2	3/60	7
Stanford Sleepiness Scale	Adults	72	6	1/60	7
Wellness Survey	Adults	.....	2	2/60	5
Dosing/Driving/Waiting	Adults	.....	2	4	576

Dated: September 25, 2013.

Glenda J. Conroy,

Executive Officer (OM Director), NIDA, NIH.

[FR Doc. 2013–23972 Filed 10–1–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Meeting

Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the National Cancer Institute Board of Scientific Advisors.

The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting.

Name of Committee: National Cancer Institute Board of Scientific Advisors.

Date: November 7, 2013.

Time: 9:00 a.m. to 5:00 p.m.

Agenda: Director's Report: Ongoing and New Business; Reports of Program Review Group(s); and Budget Presentations, Reports of Special Initiatives; RFA and RFP Concept Reviews; and Scientific Presentations.

Place: National Institutes of Health, Building 31, C-Wing, 6th Floor, Conf. Rm. 10, 31 Center Drive, Bethesda, MD 20892.

Contact Person: Paulette S. Gray, Ph.D., Executive Secretary, Division of Extramural Activities, National Cancer Institute—Shady Grove, National Institutes of Health, 9609 Medical Center Drive, 7th Floor, Rm. 7W444, Bethesda, MD 20892, 240–276–6340, *grayp@mail.nih.gov.*

Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person.

In the interest of security, NIH has instituted stringent procedures for entrance onto the NIH campus. All visitor vehicles, including taxicabs, hotel, and airport shuttles will be inspected before being allowed on campus. Visitors will be asked to show one form of identification (for example, a government-issued photo ID, driver's license, or passport) and to state the purpose of their visit.

Information is also available on the Institute's/Center's home page: *http://deainfo.nci.nih.gov/advisory/bsa/bsa.htm,* where an agenda and any additional information for the meeting will be posted when available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: September 26, 2013.

Melanie J. Gray,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2013–23961 Filed 10–1–13; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Expressions of Interest (EOI) for Chemical Defense Demonstration Projects

AGENCY: Office of Health Affairs, DHS.

ACTION: Notice of Expression of Interest.

SUMMARY: The Chemical Defense Program (CDP), under the Department of Homeland Security Office of Health Affairs (OHA), is seeking Expressions of Interest (EOI) from state, local, tribal, and territorial (SLTT) government agencies to participate in a chemical defense demonstration project relative to a specific venue (e.g., indoor sports stadium, outdoor port facility, convention center). These projects will assist communities in enhancing their preparedness to respond effectively and quickly to a catastrophic chemical event. Using the DHS Form 10088 (9/12) posted on *https://www.dhs.gov/publication/eoi-form-cdp-demonstration-project,* interested SLTT governmental agencies must submit the completed and signed form to the DHS OHA CDP.

DATES: Submit the completed and signed DHS Form 10088 (9/12), either electronically or in hard copy, no later than 45 days from the date of the **Federal Register** Notice.

ADDRESSES: Submissions of DHS Form 10088 (9/12) shall go to the following:

Hardcopy signed original document to Captain Joselito Ignacio Deputy Program Director, Chemical Defense Program Department of Homeland Security/Office of Health Affairs, 245 Murray Lane SW., Mail Stop: 0315 Washington, DC 20528; or Electronically to *Joselito.Ignacio@hq.dhs.gov.*

FOR FURTHER INFORMATION CONTACT: CAPTAIN JOSELITO IGNACIO, 202–254–5738 OR *joselito.ignacio@hq.dhs.gov.*

SUPPLEMENTARY INFORMATION: The demonstration projects are based on appropriations found in Public Law 112–74 (Consolidated Appropriations Act, 2012) and Public Law 133–6 (''The Consolidated and Further Continuing Appropriations Act, 2013''), which call for the Chemical Defense Program of DHS OHA to conduct a competitive selection of locations and venues to participate in chemical detection demonstration projects. The DHS OHA CDP will initiate, fund and manage the demonstration projects, but in close coordination with the selected SLTT government agencies and venue operators. The demonstration project will result in, among other things: (a) A review of current community preparedness capabilities as well as gaps protecting from and responding to a catastrophic chemical incident; (b) community and venue-specific risk assessments, based on likely scenarios, to provide information on chemical threats; (c) technology alignment to include review of existing or intended detect-to-warn or detect-to-treat capabilities in communities; (d) optimizing the communities' response system through decision analysis and the development of a concept of operations plan that defines common mission, roles, responsibilities and key actions necessary for responding to these events; and (e) exercise evaluation using the Homeland Security Exercise and Evaluation Program (HSEEP) process. Through successful completion of these demonstration projects, the selected communities will have enhanced preparedness of their emergency management, first responder, and first receiver groups with the knowledge, skills and tools to act swiftly and competently in protecting lives and restoring peace of mind in response to a catastrophic chemical incident.

As stated, DHS will conduct a competitive selection. A DHS selection panel, led by the DHS OHA CDP, will carefully review the completed and signed DHS Form 10088 (9/12) and rate each submission using weighted criteria on the basis of (a) chemical threat risk (which the DHS Chemical Terrorism Risk Assessments and SLTT government agencies' input will inform); (b) community interest to host a demonstration project; and (c) reasons given for desiring a demonstration project hosted in this community and specific venue. Numerically sequenced from high to low values, top tiered communities are then selected to have these projects conducted in their locations. All communities will receive notification of the selection results. Once selected, DHS OHA CDP will enter